Utilizing Artificial Intelligence to Detect Cardiac Amyloidosis in Patients with Severe Aortic Stenosis: A Step Forward to Diagnose the Underdiagnosed

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2024 Sep 27

PMID 39331132

Authors

Steven A Muller

Laurenz Hauptmann

Christian Nitsche

Marish Ifj Oerlemans

Affiliations

Soon will be listed here.

References

Dona C, Nitsche C, Koschutnik M, Heitzinger G, Mascherbauer K, Kammerlander A . Unveiling Cardiac Amyloidosis, its Characteristics, and Outcomes Among Patients With MR Undergoing Transcatheter Edge-to-Edge MV Repair. JACC Cardiovasc Interv. 2022; 15(17):1748-1758. DOI: 10.1016/j.jcin.2022.06.009. View

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A . Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021; 42(16):1554-1568. PMC: 8060056. DOI: 10.1093/eurheartj/ehab072. View

Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Waddington-Cruz M . Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018; 379(11):1007-1016. DOI: 10.1056/NEJMoa1805689. View

Oerlemans M, Rutten K, Minnema M, Raymakers R, Asselbergs F, de Jonge N . Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019; 27(11):525-536. PMC: 6823341. DOI: 10.1007/s12471-019-1299-1. View

Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba M, Lopez-Sainz A, Giannoni A . Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2019; 13(4):909-920. DOI: 10.1016/j.jcmg.2019.10.011. View

Aimo A, Tomasoni D, Porcari A, Vergaro G, Castiglione V, Passino C . Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis. Eur J Heart Fail. 2023; 25(4):510-514. DOI: 10.1002/ejhf.2824. View

Davies D, Redfield M, Scott C, Minamisawa M, Grogan M, Dispenzieri A . A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2022; 7(10):1036-1044. PMC: 9453635. DOI: 10.1001/jamacardio.2022.1781. View

Tini G, Milani P, Zampieri M, Caponetti A, Fabris F, Foli A . Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study. Eur J Heart Fail. 2023; 25(6):845-853. DOI: 10.1002/ejhf.2823. View

Brons M, Muller S, Rutten F, van der Meer M, Vrancken A, Minnema M . Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience. Eur Heart J Open. 2022; 2(2):oeac011. PMC: 9242028. DOI: 10.1093/ehjopen/oeac011. View

10.

Gonzalez-Lopez E, Gagliardi C, Dominguez F, Quarta C, de Haro-Del Moral F, Milandri A . Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017; 38(24):1895-1904. DOI: 10.1093/eurheartj/ehx043. View

11.

Muller S, Achten A, van der Meer M, Zwetsloot P, Sanders-van Wijk S, van der Harst P . Absence of an increased wall thickness does not rule out cardiac amyloidosis. Amyloid. 2024; 31(3):244-246. DOI: 10.1080/13506129.2024.2348681. View

12.

Muller S, Peiro-Aventin B, Biagioni G, Tini G, Saturi G, Kronberger C . Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis. Eur J Heart Fail. 2024; 26(9):2025-2034. DOI: 10.1002/ejhf.3339. View

13.

Nitsche C, Aschauer S, Kammerlander A, Schneider M, Poschner T, Duca F . Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020; 22(10):1852-1862. PMC: 7687139. DOI: 10.1002/ejhf.1756. View

14.

Nitsche C, Scully P, Patel K, Kammerlander A, Koschutnik M, Dona C . Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2020; 77(2):128-139. PMC: 7805267. DOI: 10.1016/j.jacc.2020.11.006. View

15.

Shiri I, Balzer S, Baj G, Bernhard B, Hundertmark M, Bakula A . Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis. Eur J Nucl Med Mol Imaging. 2024; 52(2):485-500. PMC: 11732884. DOI: 10.1007/s00259-024-06922-4. View

16.

Nitsche C, Koschutnik M, Dona C, Radun R, Mascherbauer K, Kammerlander A . Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2022; 15(7):e014115. DOI: 10.1161/CIRCIMAGING.122.014115. View

17.

Scully P, Patel K, Saberwal B, Klotz E, Augusto J, Thornton G . Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients. JACC Cardiovasc Imaging. 2020; 13(10):2177-2189. PMC: 7536272. DOI: 10.1016/j.jcmg.2020.05.029. View

18.

Spielvogel C, Haberl D, Mascherbauer K, Ning J, Kluge K, Traub-Weidinger T . Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study. Lancet Digit Health. 2024; 6(4):e251-e260. DOI: 10.1016/S2589-7500(23)00265-0. View